StockData
Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc. (TSHA) stock

TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$4.00−0.06 (-1.48%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Taysha Gene Therapies enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Taysha Gene Therapies's enterprise value was $986.15M on Nov 11, 2026, against $1.05B a year earlier. Over the last 5 years it ranged from -$927.18K to $1.73B, with a median of $269.87M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$986.15M-21.7%
2025Dec 31, 2025$1.26B+425.4%
2024Dec 31, 2024$239.83M+16.9%
2023Dec 29, 2023$205.19M+112.6%
2022Dec 30, 2022$96.52M-66.4%
2021Dec 31, 2021$287.25M-60.3%
2020Dec 31, 2020$723.55M–

More Taysha Gene Therapies figures

See a number that looks wrong?